The association of 18F-FDG PET/CT and biomarkers in confirming coronary microvascular dysfunction

Influence of fasting plasma glucose-lowering rate on BNP levels in type 2 diabetes mellitus patients with coronary microcirculation dysfunction

AIM

The aim was to analyze the influence of fasting plasma glucose-lowering rate (FPGLR) on plasma BNP levels in type 2 diabetes mellitus (T2DM) patients with coronary microcirculation dysfunction (CMD) and to determine the optimal FPGLR for these patients.

METHODS

A total of 170 T2DM patients who received intensive glucose-lowering therapy during hospitalization in the First Affiliated Hospital of Harbin Medical University were enrolled. Ninety-two patients with CMD and 78 patients without CMD were assigned to a study and a control group, respectively. The study group was stratified as S1 (4.1 ~ 6.0 mmol·L^-1·day^-1), S2 (2.1 ~ 4.0 mmol·L^-1·day^-1), and S3 (≤ 2.0 mmol·L^-1·day^-1) by different FPGLR, and the same in the control group (C1, C2, and C3). The plasma BNP levels with the same FPGLR were compared between the study and the control group, and patients with a different FPGLR in the study group were also compared.

RESULTS

In the study and the control group, the BNP level in S1 was significantly higher than that in C1 (87 vs. 12 pg/ml, P < 0.001), although there was no significant difference between S2 and C2, S3 and C3. In the study group, the BNP level in S1 was significantly higher than that in S2 (87 vs. 22 pg/ml, P < 0.001) and S3 (87 vs. 15 pg/ml, P < 0.001), but there was no significant difference between S2 and S3.

CONCLUSION

Rapid intensive glucose-lowering may lead to increased plasma BNP levels in T2DM patients with CMD. Optimal FPGLR for these patients was determined to be no more than 4.0 mmol·L^-1·day^-1.

Novel nuclear medical procedures in the detection of microvascular dysfunction

Coronary microvascular dysfunction is present in two-thirds of patients showing symptoms and signs of myocardial ischemia. Their microcirculation has abnormalities due to endothelial and smooth muscle cell dysfunction. Impairment of this mechanism causes a high risk of adverse cardiovascular event. Diagnosing coronary microvascular dysfunction is challenging. Guidelines recommend the use of nuclear medicine procedures in the above-mentioned indications. Myocardial perfusion imaging with positron emission tomography is a novel procedure with high diagnostic accuracy and quality of images. It has short acquisition, low effective radiation dose and prognostic factors. There are still unknowns about this procedure and all its benefits.

[Advancement of imaging technology for coronary microcirculation dysfunction assessment]

Coronary microcirculation dysfunction (CMVD) is an important risk factor for the prognosis of re-perfused ischemic heart. Recent studies showed that the evaluation of CMVD has significant impact on both the early diagnosis of heart diseases relevant to blood supply and prognosis after myocardial reperfusion. In this review, the definition of CMVD from the perspective of pathophysiology was clarified, the principles and features of the state-of-the-art imaging technologies for CMVD assessment were reviewed from the perspective of engineering and the further research direction was promoted.